Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MEETINGS - RAPS (Regulatory Affairs Professional Society) Medical Device Conference & Tabletop Exhibition (US) March 2002:

This article was originally published in Clinica

Executive Summary

RAPS Medical Device Conference & Tabletop Exhibition will be held on March 18-20 2002 at The Fairmont San Francisco, San Francisco, US. Topics include an analysis of efforts to harmonise global quality system requirements, the strategic role of regulatory affairs throughout the product lifecycle and global business strategies. The first day is taken up with series of four workshops designed to develop a greater understanding of premarket notifications and approvals, investigational device exemption and necessary preparations for ISO 13485. Over 25 exhibitors will showcase their products and services. Further details from RAPS on tel: +1 301 770 2920; fax: +1 301 770 2924; email: [email protected] www.raps.org

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT064362

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel